E-Mail
IMAGE: A research team at the Wyss Institute and Harvard Medical School has developed a nasal swab collection technology enabling high-throughput automated sample processing for molecular diagnosis of respiratory diseases including. view more
Credit: Wyss Institute at Harvard University
(Boston) The Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) and the Massachusetts-based startup Rhinostics announced today that the University s sample collection swab and high-throughput automation technologies have been licensed to Rhinostics. The company will further develop and commercialize automated and multiplexed solutions for processing nasal samples from people suspected to have COVID-19 or other respiratory infectious diseases. The license was coordinated by Harvard s Office of Technology Development (OTD) in accordance with the University s commitment to the COVID-19 Technology Access Framework.
Harvard University licenses its nasal swab collection technology, developed at the Wyss Institute and Harvard Medical School, to Mass startup Rhinostics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Duration of WHO-declared COVID-19 pandemic
(a) Wellcome Trust Publishers Pledge
The first pandemic-related IP pledge addressed copyrights. On January 31, 2020, the Wellcome Trust, a large UK-based medical charity, led a group of approximately thirty scientific and medical publishers in committing to make all peer-reviewed research publications relating to COVID-19 available without charge on an open access basis. The signatories included Elsevier, Cell Press, Karger, the JAMA Network, the New England Journal of Medicine, Oxford University Press, Springer Nature, Taylor & Francis, Wiley, and Wolters Kluwer. The initiative echoed earlier Wellcome-led pledges of similar scope made with respect to research concerning the Zika and Ebola outbreaks.
New diagnostic platform can rapidly measure COVID-19-related biomarkers
The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
The research collaboration further cements both parties commitment to bringing the Wyss multiplexed electrochemical detection system forward as a diagnostic tool during the pandemic and follows a licensing agreement coordinated by Harvard s Office of Technology Development (OTD) in November 2020 that granted The iQ Group Global non-exclusive, term-limited access to the eRapid technology in accordance with the Univer
E-Mail
IMAGE: The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with the GBS s transistor technology in developing a multiplexed. view more
Credit: Wyss Institute at Harvard University
(BOSTON) The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
vimarsana © 2020. All Rights Reserved.